How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,333 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

impairment). Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale [ Time Frame: Days 1 (baseline) and 91 ] Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort (...) in brain glucose utilization, using FDG-PET voxel-based analysis. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. Explore

2011 Clinical Trials

162. D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

compulsive disorder. This study represents an innovative approach in translating bench research findings into clinical research and testing a new approach for optimizing an effective psychotherapy with a safe non-psychotropic medication. Condition or disease Intervention/treatment Phase Obsessive-compulsive Disorder Behavioral: Cognitive-behavioral therapy Drug: d-cycloserine Drug: Pill placebo Phase 3 Detailed Description: Obsessive-compulsive disorder (OCD) affects 1-2% of children, runs a chronic (...) course without treatment, and is associated with considerable functional impairment and poor quality of life. Although most patients with OCD respond to cognitive-behavioral therapy (CBT) or pharmacotherapy with a serotonin reuptake inhibitor (SRI), a substantial number of youth remain symptomatic after receiving these therapies. Pharmacological interventions with SRIs are only moderately efficacious, rarely produce remission, may be accompanied by side effects, and may not be an acceptable

2011 Clinical Trials

163. Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

scan performed in the last six months. Patients with cognitive impairment at screening, defined as at least one test of the Rao's Brief Repeatable Battery with scores falling outside the 90th percentile of the normative data. Exclusion Criteria: Patients who had already been treated with multiweekly interferon (interferon beta 1b, or beta 1a multiweekly) and had an unsatisfactory response according to the judgment of the investigator. Patients with hyperactive forms of the MS disease according (...) ): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive

2011 Clinical Trials

164. Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder

(in the patient's and clinician's opinion) and the primary reason for seeking treatment Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale Exclusion Criteria: Current clinically significant suicidality and/or score on the BDI-II suicide item (#9) > 1 Any clinical features requiring a higher level of care Mental retardation or borderline intellectual functioning (estimated IQ < 80 on the Wechsler Abbreviated Scale of Intelligence) or dementia, brain damage, or other cognitive impairment (...) chronic, and common disorder consisting of distressing or impairing preoccupation with perceived defects in one's physical appearance. Individuals with BDD have very poor psychosocial functioning and high rates of hospitalization and suicidality. Because BDD differs in important ways from other disorders, psychotherapies for other disorders are not adequate for BDD. Despite BDD's severity, there is no adequately tested psychosocial treatment (psychotherapy) of any type for this disorder. This study

2011 Clinical Trials

165. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. (PubMed)

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD.Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies (...) the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline

2009 International Journal of Geriatric Psychiatry

166. Guidelines for diagnosing and managing pediatric concussion

://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=sort. Accessed May 8, 2014. 2 Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56. Chapter: Tipsheet Guidelines for Diagnosing and Managing Pediatric Concussion 3 Tipsheet / List of Tools Tipsheet for Health Care Professionals In Advance (before the first activity) Number Evidence 0.4 Consider baseline neuro-cognitive testing (...) for Diagnosing and Managing Pediatric Concussion 5 Tipsheet / List of Tools 5.4c(i) Assess for persistent cognitive difficulties. B 5.4c(ii) Manage any cognitive impairments. B 5.4d(i) Assess for balance and vestibular impairments. B 5.4d(ii) Assess for benign positional vertigo. B 5.4d(iii) Refer for further assessment and treatment if balance and/or vestibular system are dysfunctional. B 5.4e(i) Assess ongoing vision dysfunctions. B 5.4e(ii) Refer children/adolescents who have changes in functional vision

2019 CPG Infobase

167. Vagus Nerve Stimulation for chronic major depressive episodes

regional cerebral blood flow to multiple brain areas. VNS settings are adjusted using a magnetic wand placed on the skin surface overlying the pulse generator. The estimated battery life is 10 years. MSAC noted that the applicant had agreed to amend the item descriptor to ‘four or more classes of antidepressants’, but also considered that it was unclear what defined an ‘adequate’ response. MSAC also considered that, of the six proposed MBS items for VNS implantation, it was unclear who would (...) and Victoria. This may create issues around equity of access if adopted. 6. Proposal for public funding There are six proposed MBS items for VNS implantation, relating to the placement of the generator, repositioning or removal of the generator, placement of the lead, repositioning or removal of the lead, device programming and replacement of the battery. These items mirror the same items that were approved for VNS in the treatment of refractory epilepsy. The proposed MBS item descriptors are presented

2019 Medical Services Advisory Committee

168. Iron Deficiency – Diagnosis and Management

ages: tiredness, restless legs, inattention, poor school performance, irritability/depression, growth retardation, unexplained cognitive and intellectual impairment, breath-holding spells, developmental delay, pica/pagophagia Infants: poor feeding, lethargy, failure to thrive, cardiomegaly, tachypnea Adolescents: presyncope, syncope, headache, irritability, fatigue, exercise intolerance, restless legs Diagnosis Serum ferritin is the diagnostic test of choice for iron deficiency. The ferritin cut (...) intolerance Headaches Restless leg syndrome Irritability/depression Angular cheilitis Pica/pagophagia (ice craving) Decreased aerobic work performance Hair loss Adverse pregnancy outcome Impaired immune function * Iron therapy may improve restless legs syndrome severity and restlessness. Iron supplementation is recommended if serum ferritin is ≤ 75 ug/L. , Testing Initial investigational tests The recommended initial tests for iron deficiency and for IDA, in otherwise well patients, should usually

2019 Clinical Practice Guidelines and Protocols in British Columbia

169. Evidence Map - Art Therapy

/dementia, 47-53 of which 1 was an RCT. 53 In addition, there were 3 impact evaluations related to Alzheimer’s/dementia that combined art therapy with music, horticulture activity, memory training, and cognitive stimulation activities. 54 with music, 55 and with choral singing 56 of which 1 was an RCT. 56 There were 2 systematic reviews related to Alzheimer’s/dementia that included a mixture of art therapy and other treatment modality. Both were rated low confidence. 57,58 Schizophrenia/Psychosis (...) trial. Art Therapy. 2007;24(2):71-75. 44. Rawtaer I, Mahendran R, Yu J, Fam J, Feng L, Kua EH. Psychosocial interventions with art, music, Tai Chi and mindfulness for subsyndromal depression and anxiety in older adults: A naturalistic study in Singapore. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. 2015;7(1758-5872 (Electronic)):240-250. 45. Im ML, Lee JI. Effects of art and music therapy on depression and cognitive function of the elderly. Technology

2019 Veterans Affairs Evidence-based Synthesis Program Reports

170. Early Support

evidence 15 III-2 A comparative study with concurrent controls (i.e. non- randomised experimental trials, cohort studies, case-control studies, interrupted time series studies with a control group) 1 III-3 A comparative study without concurrent controls (i.e. historical control study, two or more single arm studies, interrupted time series studies without a parallel control group) 3 IV Case series with either post-test or pre-test/post-test outcomes 8 See Appendix 2 for explanation of NHMRC levels (...) participation in classroom activities. (24) One PD program, the Freedom Writers Institute (FWI), found that students taught by educators who had received the training reported higher levels of school engagement than those with educators in the control group. (25) In the FWI program, school engagement was defined as more than academic engagement, and included the provision of ongoing support around the young person’s cognitive, behavioural and emotional interactions in the classroom and school settings

2019 Sax Institute Evidence Check

171. Istradefylline (Nourianz) - Parkinson's disease

database: 23 8.3. Adequacy of Applicant’s Clinical Safety Assessments 23 8.3.1. Issues Regarding Data Integrity and Submission Quality 24 8.3.2. Categorization of Adverse Events 24 8.3.3. Routine Clinical Tests 25 8.4. Safety Results 26 8.4.1. Deaths 26 8.4.2. Serious Adverse Events 29 8.4.3. Dropouts and/or Discontinuations Due to Adverse Effects 35 8.4.4. Significant Adverse Events 37 8.4.5. Treatment Emergent Adverse Events and Adverse Reactions 39 8.4.1. Laboratory Findings 49 8.4.2. Vital Signs 56 (...) of TEAEs. The duration of follow up of TEAEs appeared acceptable given that the terminal half-life of istradefylline (82.7 hours). 8.3.3. Routine Clinical Tests The schedule of assessments for clinical laboratory tests (chemistry, hematology, and urine analysis) were as per the individual study protocols. Seven out of eight studies in Pool 1 had clinical laboratory assessments at baseline (Study Day -1), and then Week 2, 4, 8, and 12. Study 6002-014 had clinical laboratory assessments on Study Days 1

2019 FDA - Drug Approval Package

172. Individualised funding interventions to improve health and social care outcomes for people with a disability

nineteen titles in total. One of the studies was an unpublished report (available online), while the remaining six were reported in both unpublished reports and published peer-reviewed journal articles. All studies were English language and the majority were based in the United States (n=5). One study was a ‘quasi-experimental controlled longitudinal survey’, three were ‘randomised, controlled cross-sectional surveys’ and three were ‘randomised controlled before and after studies’. A total of 4,834 (...) strategy as it was anticipated that this would potentially lead to the omission of relevant studies. Furthermore, the mixed methods approach on which this review is based, led to broad inclusion criteria for study designs (Appendix 2 – methods paper). All search strings are provided in Appendix 1. A sample search string is outlined below: ‘intellectual impairment'/exp OR 'disability'/exp OR handicap OR ((people OR person* OR individ*) NEAR/3 (disabil* OR disable*)):ab,ti OR insanity OR (mental NEAR/1

2019 Campbell Collaboration

173. Public health service provision by community pharmacies: a systematic map of evidence

The included studies 88 9.3 Alcohol 88 9.4 Services for people who inject drugs 91 10 Obesity and weight management 98 10.1 Introduction 98 10.2 Included studies 98 11 Other health conditions 103 11.1 Introduction 103 11.2 Bowel disease and gastrointestinal conditions 106 11.3 Early cancer awareness 108 11.4 Chronic kidney disease (CKD) and renal impairment 112 11.5 Dementia and cognitive impairment 113 11.6 Depression 114 11.7 Low back pain 115 11.8 Migraine and headache 116 Public health service (...) health services via community pharmacies (n=15). The number of studies identified for each of these and other study foci are outlined in Figure 3.5. 1 1 1 1 1 1 1 2 2 2 4 7 9 12 Chronic kidney disorder (CKD) Dementia and cognitive impairment Depression Low back pain Migraine/headache Osteoarthritis Urinary tract infections (UTI) Skin disorders Sleep disorders Streptococcal infections Bowel disorders and GI conditions Cancer Respiratory health Osteoporosis Other health conditions The evidence-base

2019 EPPI Centre

174. What helps to support people affected by Adverse Childhood Experiences? A Review of Evidence

around’ 30 Continuity and Dependability – ‘they just leave you after a while’ 31 Flexibility and Control – ‘They don’t tell you what to do’ 32 4 Overview: Interventions to support people affected by Adverse Childhood Experiences (RoR) 33 4.1 Flow of literature through the review 33 4.2 Quality assessment 34 4.3 Best evidence synthesis 34 4.4 Classification of interventions 36 4.5 Summary and key findings 36 4.6 Findings 36 Cognitive Behavioural Therapy (CBT) 37 Psychological therapies other than (...) Cognitive Behavioural Therapy (CBT) 39 Psychoeducation 42 Treatments aimed predominately at parents 44 Parent / foster carer training 45 Cross-sector support 47 Educational 49 Housing and life skills 50 Foster care / out-of-home care 52 5 Stakeholder workshop 53 5.1 Findings 53 Inflexibility of school system and teachers’ attitudes 53 ACEs impact people in different ways and at different times 53 Ethnic background 54 Recreation and practical skills 54 Counselling and talking therapies 54 Ways to measure

2019 EPPI Centre

175. Management of stable angina

questionnaire using a set of common daily living items. 210 Simple exercise testing may further refine risk assessment. The failure to climb two flights of stairs, which is the equivalent of more than four METs, is a good predictor of mortality associated with thoracic surgery and complications after major non-cardiac surgery. 211 Cardiopulmonary exercise testing has been used to identify high-risk groups for major non-cardiac surgery. The measurement of anaerobic threshold may be a better predictor than (...) in SIGN 50: a guideline developer’s handbook, 2015 edition (www.sign.ac.uk/guidelines/fulltext/50/ index.html). More information on accreditation can be viewed at www.nice.org.uk/ accreditation Healthcare Improvement Scotland (HIS) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion/belief and sexual orientation. SIGN guidelines are produced using a standard methodology that has been

2018 SIGN

176. Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines

A]. ii. Echocardiography should be considered in cases where a stroke mechanism has not been identified [Evidence Level C]. 1.3 Functional assessment i. Selected patients with transient ischemic attack or ischemic stroke should be assessed for neurological impairments and functional limitations when appropriate (e.g. cognitive evaluation, screening for depression, screening of fitness to drive, need for potential rehabilitation therapy, and assistance with activities of daily living), especially (...) for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease

2018 CPG Infobase

177. Cardiac arrhythmias in coronary heart disease

and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2015 edition (www.sign.ac.uk/guidelines/fulltext/50/ index.html). More information on accreditation can be viewed at www.nice.org.uk/ accreditation Healthcare Improvement Scotland (HIS) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion/belief and sexual orientation. SIGN guidelines (...) assessment of LV function for risk stratification at least six weeks following the acute event. 2.3 ARRHYTHMIAS ASSOCIATED WITH CHRONIC CORONARY HEART DISEASE/LEFT VENTRICULAR DYSFUNCTION R Rate control is the recommended strategy for management of patients with well-tolerated atrial fibrillation. R In patients with permanent AF or persistent AF following a rate-control strategy and a resting heart rate >110 bpm, appropriate rate-control therapy should be instituted with an initial target of resting

2018 SIGN

178. Statins for the primary prevention of cardiovascular events

, the Scandinavian Simvastatin Survival Study (the 4-S study), were reported. 13 Researchers tested simvastatin, sold by Merck as Zocor, on 4444 patients with high cholesterol and existing heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their risks of dying from a myocardial infarction were reduced by 42%. At that moment several other pharmaceutical companies were developing similar products. Because of the high price, reimbursement of statins (...) the sample proportion is known (1/40 among subjects younger than 65 and 1/20 among subjects aged 65 years and older), this permits to extrapolate the data to the Belgian population. This extrapolation was realized thanks to the SAS survey procedure. To check the validity of this extrapolation we test the concordance of the extrapolated data with the official data published by RIZIV – INAMI. Concordance of the extrapolated data with RIZIV – INAMI data The exact number of users and the number of DDD’s

2019 Belgian Health Care Knowledge Centre

179. Diagnosis and management of epilepsy in adults

but usually resolve with time. 126 Sedation may be less with AEDs licensed from, for example, 1990 onwards, particularly lamotrigine, oxcarbazepine and levetiracetam. 94 Many patients on long term AED therapy report cognitive adverse effects (see section 4.6.5) but studies to confirm this have been contradictory and confounded by the effects of chronic epilepsy. 142, 143 Polytherapy is probably associated with more cognitive adverse effects than monotherapy. 144 Impaired bone health is associated (...) be viewed at www.evidence.nhs.uk Healthcare Improvement Scotland (HIS) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion/belief and sexual orientation. SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality aims are addressed in every guideline. This methodology is set out in the current version of SIGN 50, our

2018 SIGN

180. Optimisation of RIZIV – INAMI lump sums for incontinence

evaluation and management 40 2.4.6 Care pathway for the management of urine incontinence in men 41 2.4.7 Care pathway for the management of urine incontinence in women 45 2.5 MANAGEMENT OF URINARY INCONTINENCE IN THE FRAIL ELDERLY AND THE COGNITIVELY IMPAIRED 49 2.5.1 Conservative options 49 2.5.2 Pharmacological treatment 50 2.5.3 Surgical treatment in the frail older person 52 2.6 MANAGEMENT OF URINARY INCONTINENCE IN CHILDREN 56 2.6.1 Initial assessment 56 2.6.2 Initial management 57 2.6.3 Specialised (...) and severe dementia are individual risk factors for UI. Overflow of urine commonly presents when the bladder is continuously full, with or without weakening of the bladder muscles, and when there is no urge to urinate or bladder contractions. Predisposition factors for UI in men are less well documented in the literature and include presence of lower urinary tract symptoms (LUTS), urinary tract infections, functional and cognitive impairment, diabetes, neurological disorders, and surgery e.g

2019 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>